Dergiler / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 6

Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study

Sayfa
354–362
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The results of this study help understand the potential misuse of aspirin in a real-world setting. (Anatol J Cardiol 2018; 20: 354-62)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:signifiObjective:The aim of this study was to describe the current status of aspirin use and the demographic characteristics of patients on aspirin for primary and secondary prevention of cardiovascular diseases.Methods: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) trial was a multicenter, cross-sectional, and observational study conducted in Turkey.
📊
Temel Bulgular & Veri:The study was planned to include 5000 patients from 14 cities in Turkey.
💡
Sonuç & Katkı:The results of this study help understand the potential misuse of aspirin in a real-world setting. (Anatol J Cardiol 2018; 20: 354-62)
🔬Tür:Araştırma Makalesi
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

signifiObjective:The aim of this study was to describe the current status of aspirin use and the demographic characteristics of patients on aspirin for primary and secondary prevention of cardiovascular diseases.Methods: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) trial was a multicenter, cross-sectional, and observational study conducted in Turkey. The study was planned to include 5000 patients from 14 cities in Turkey. The data were collected at one visit, and the current clinical practice regarding aspirin use was evaluated (ClinicalTrials.gov number NCT03387384).Results: The study enrolled all consecutive patients who were admitted to the outpatient cardiology clinics from March 2018 until June 2018. Patients should be at least 18 years old, have signed written informed consent, and on aspirin (80–325 mg) therapy within the last 30 days. Cardiologists from the hospital participates in the study. Patients were divided into 2 categories according to presence or absence of atherosclerotic cardiovascular disease, namely secondary prevention group and primary prevention group, respectively. The appropriate use of aspirin in the primary and secondary prevention groups was assessed according to the European Society of Cardiology guidelines and US Preventive Services Task Force. The patients’ gastrointestinal bleeding risk factors and colorectal cancer risk were evaluated.Conclusion: The ASSOS registry will be the most comprehensive and largest study in Turkey evaluating the appropriateness of aspirin use. The results of this study help understand the potential misuse of aspirin in a real-world setting. (Anatol J Cardiol 2018; 20: 354-62)

🔖

Bu Makaleye Atıf Yap

ÇELİK, O., ÇİL, C., ÖZLEK, B., ÖZLEK, E., DOĞAN, V., BAŞARAN, Ö., DEMİRCİ, E., BEKAR, L., KALÇIK, M., KARAARSLAN, O., YETİM, M., DOĞAN, T., DEMİR, V., KALKAN, S., ÖZKAN, B., HİDAYET, Ş., TAYLAN, G., KÜÇÜKSU, Z., ÇELİK, M. Y., EFE, S. Ç., ASLAN, O., BİTEKER, M. (2018). Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 6, 354–362. https://ajindex.com/articles/366695

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Curr Atheroscler Rep 2017
  2. [No authors listed]. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988
  3. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008
  4. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials. Lancet 2009
  5. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002
  6. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014
  7. e139–e228. 7. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016
  8. e123-55. 8. de Gaetano G
  9. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people